ProCE Banner Activity

DREAMM-2: Ocular Safety During Phase II Study of Belantamab Mafodotin in R/R MM

Slideset Download
Conference Coverage
In patients with R/R MM receiving belantamab mafodotin, ocular AEs were common but manageable, with the majority of patients recovering while remaining on treatment.

Released: December 14, 2020

Expiration: December 13, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology